In breast cancer 96, prostate cancer 96, and OSCC 97, JMJD5 is known to regulate the p53/nuclear factor-kappaB (NF-κB) pathway, the regulation of the cyclin A1 coding area, and as a dual coactivator of AR and PKM2 that integrates the AR/EZH2 network and metabolism of tumour. Here, AR is linked to breast carcinoma.